Private Wealth Partners LLC Has $672,000 Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Private Wealth Partners LLC lowered its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 33.7% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,000 shares of the biopharmaceutical company's stock after selling 3,050 shares during the period. Private Wealth Partners LLC's holdings in Gilead Sciences were worth $672,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in GILD. Brighton Jones LLC boosted its holdings in shares of Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock worth $1,326,000 after buying an additional 2,450 shares during the period. Venturi Wealth Management LLC boosted its holdings in shares of Gilead Sciences by 78.0% in the fourth quarter. Venturi Wealth Management LLC now owns 2,658 shares of the biopharmaceutical company's stock worth $246,000 after buying an additional 1,165 shares during the period. Kestra Investment Management LLC boosted its holdings in shares of Gilead Sciences by 51.1% in the fourth quarter. Kestra Investment Management LLC now owns 3,789 shares of the biopharmaceutical company's stock worth $350,000 after buying an additional 1,281 shares during the period. Global Retirement Partners LLC boosted its holdings in shares of Gilead Sciences by 2.2% in the fourth quarter. Global Retirement Partners LLC now owns 8,982 shares of the biopharmaceutical company's stock worth $830,000 after buying an additional 194 shares during the period. Finally, Sunpointe LLC boosted its holdings in shares of Gilead Sciences by 12.0% in the fourth quarter. Sunpointe LLC now owns 4,654 shares of the biopharmaceutical company's stock worth $430,000 after buying an additional 500 shares during the period. Institutional investors and hedge funds own 83.67% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Bank of America raised their target price on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a report on Wednesday, March 5th. Morgan Stanley raised their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Cantor Fitzgerald started coverage on shares of Gilead Sciences in a report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price target for the company. Wells Fargo & Company raised their price target on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Finally, Oppenheimer reduced their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research note on Friday, April 25th. Nine investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $110.55.

Gilead Sciences Stock Performance

GILD stock traded up $0.50 on Friday, reaching $108.50. 23,266,621 shares of the company were exchanged, compared to its average volume of 7,756,139. Gilead Sciences, Inc. has a 12 month low of $66.01 and a 12 month high of $119.96. The stock's fifty day moving average price is $106.16 and its 200 day moving average price is $102.74. The firm has a market capitalization of $134.97 billion, a PE ratio of 22.84, a PEG ratio of 0.70 and a beta of 0.29. The company has a debt-to-equity ratio of 1.16, a current ratio of 1.37 and a quick ratio of 1.23.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The business had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. During the same quarter in the previous year, the firm posted ($1.32) earnings per share. Gilead Sciences's revenue was down .3% compared to the same quarter last year. On average, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.91%. The ex-dividend date is Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is currently 66.53%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction on Thursday, May 15th. The shares were sold at an average price of $99.82, for a total value of $249,550.00. Following the sale, the chief financial officer now owns 165,674 shares of the company's stock, valued at $16,537,578.68. The trade was a 1.49% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Johanna Mercier sold 28,000 shares of the business's stock in a transaction on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the completion of the sale, the insider now directly owns 121,152 shares in the company, valued at $13,026,263.04. This trade represents a 18.77% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 48,500 shares of company stock valued at $5,236,245 in the last 90 days. 0.27% of the stock is currently owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.